Skip to main content

Primary Electrical Cardiac Diseases

 


Primary Electrical Cardiac Diseases: A Clinician’s Overview of Mechanisms & Management

Primary electrical cardiac diseases—often called channelopathies or primary arrhythmic disorders—are conditions where the heart’s electrical system is abnormal despite a structurally normal heart. These disorders can cause palpitations, syncope, seizures, or sudden cardiac death, especially in young individuals with otherwise normal echocardiograms.

Below is a simple, practical guide to the major primary electrical cardiac diseases and their management.

---

1. Long QT Syndrome (LQTS)


A genetic disorder of delayed myocardial repolarization, leading to prolonged QT interval and risk of torsades de pointes.


Red Flags


Syncope with emotion, exertion, or swimming


Family history of sudden death


QTc ≥ 480–500 ms on ECG



Management


Ξ²-blockers (Nadolol or Propranolol preferred)


Avoid QT-prolonging medications


ICD for high-risk or survivors of cardiac arrest


Left cardiac sympathetic denervation (LCSD) in refractory cases


Genetic screening of family members



---


2. Short QT Syndrome (SQTS)


Opposite of LQTS: QTc ≤ 330–360 ms, causing high atrial and ventricular arrhythmic risk.


Management


ICD is the mainstay


Quinidine may be used as adjunct therapy to prolong QT


Screening of first-degree relatives


---


3. Brugada Syndrome


A sodium-channel disorder causing coved ST elevation in V1–V3 and high risk of VF, especially in sleep.


Triggers


Fever


Large meals/alcohol


Sodium-blocking drugs



Management


Aggressive fever control


Avoid contraindicated drugs


ICD for symptomatic patients or spontaneous type-1 ECG with syncope


Quinidine for arrhythmia suppression in selected cases


Epicardial ablation of RVOT substrate in recurrent VF (“Brugada storm”)




---


4. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)


Normal resting ECG; exercise or emotional stress triggers bidirectional or polymorphic VT.


Management


Ξ²-blockers without intrinsic sympathomimetic activity (Nadolol)


Flecainide added if breakthrough arrhythmias


Avoid strenuous/emotional triggers


ICD only if arrhythmias persist despite optimal therapy


Family screening essential


---


5. Wolff–Parkinson–White (WPW) Syndrome


Presence of an accessory pathway causing pre-excitation and potential for AVRT or rapid AF transmission.


ECG Features


Short PR


Delta wave


Wide QRS



Management


Catheter ablation is curative and first-line in symptomatic or high-risk pathways


Avoid AV nodal blockers in AF with pre-excitation


Emergency management of pre-excited AF: Procainamide or DC shock




---


6. Early Repolarization Syndrome (Malignant ER Pattern)


Traditionally benign, but certain patterns (inferolateral J waves with ST elevation) increase VF risk.


Management


ICD for survivors of VF


Isoproterenol for acute VF storms


Quinidine may reduce recurrence


Lifestyle: avoid triggers; correct electrolytes




---


7. Sick Sinus Syndrome (Inherited Forms)


Rare genetic dysfunction of the sinus node causing bradycardia, pauses, chronotropic incompetence.


Management


Permanent pacemaker if symptomatic


Evaluate for associated channelopathies




---


Practical Workup in Suspected Electrical Heart Disease


1. ECG + high-lead V1–V3 placement



2. Holter monitoring / event recorder



3. Exercise test (useful in CPVT, LQTS)



4. Drug challenge (Ajmaline for Brugada, epinephrine for LQTS—specialist only)



5. Electrophysiology study for selected patients



6. Genetic testing when suspicion is high





---


When to Suspect a Primary Electrical Disease


Syncope with normal echo


Seizures misdiagnosed as epilepsy


Family history of sudden death < 40 years


No structural heart disease but recurrent arrhythmias


Event triggered by emotion, sleep, fever or exercise




---


Take-Home Messages


These diseases kill young people with structurally normal hearts—high suspicion saves lives.


ECG patterns + clinical triggers are key.


Ξ²-blockers, quinidine, ICDs, and ablation form the backbone of therapy, depending on the condition.


Family screening is crucial due to strong genetic links.



Thanks

Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.